File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: Risk of Adverse Events and Delirium after COVID-19 Vaccination in Patients Living with Dementia

TitleRisk of Adverse Events and Delirium after COVID-19 Vaccination in Patients Living with Dementia
Authors
Keywordsadverse events
COVID-19 vaccine
delirium
dementia
vaccine safety
Issue Date20-Apr-2023
PublisherElsevier
Citation
Journal of the American Medical Directors Association, 2023, v. 24, n. 6, p. 892-900 How to Cite?
Abstract

Objectives

The aim of this study was to compare incidences of adverse events of special interest (AESI) and delirium in 3 cohorts: after COVID-19 vaccination, prepandemic, and SARS-CoV-2 polymerase chain reaction (PCR) test positive.

Design

This is a population-based cohort study using electronic medical records linked with vaccination records in Hong Kong.

Setting and Participants

A total of 17,449 older people with dementia received at least 1 dose of CoronaVac (n = 14,719) or BNT162b2 (n = 2730) between February 23, 2021, and March 31, 2022. Moreover, 43,396 prepandemic and 3592 SARS-CoV-2 test positive patients were also included in this study.

Methods

The incidences of AESI and delirium up to 28 days after vaccination in the vaccinated dementia cohort were compared with the prepandemic and SARS-CoV-2 test positive dementia cohorts by calculating incidence rate ratios (IRRs). Patients who received multiple doses were followed up separately for each dose, up to the third dose.

Results

We did not detect an increased risk of delirium and most AESI following vaccination compared to the prepandemic period and those tested positive for SARS-CoV-2. No AESI group nor delirium incidence exceeded 10 per 1000 person-days in vaccinated individuals.

Conclusions and Implications

The findings provide evidence for the safe use of COVID-19 vaccines in older patients with dementia. In the short run, benefit appears to outweigh the harm due to vaccine; however, longer follow-up should be continued to identify remote adverse events.


Persistent Identifierhttp://hdl.handle.net/10722/338302
ISSN
2023 Impact Factor: 4.2
2023 SCImago Journal Rankings: 1.592
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorCheung, ECL-
dc.contributor.authorLeung, MTY-
dc.contributor.authorChen, KL-
dc.contributor.authorWan, EYF-
dc.contributor.authorLi, X-
dc.contributor.authorLai, FTT-
dc.contributor.authorWong, CKH-
dc.contributor.authorQin, XS-
dc.contributor.authorChan, EW-
dc.contributor.authorLau, KK-
dc.contributor.authorLuo, H-
dc.contributor.authorLin, CC-
dc.contributor.authorWong, ICK-
dc.contributor.authorChui, CSL-
dc.date.accessioned2024-03-11T10:27:51Z-
dc.date.available2024-03-11T10:27:51Z-
dc.date.issued2023-04-20-
dc.identifier.citationJournal of the American Medical Directors Association, 2023, v. 24, n. 6, p. 892-900-
dc.identifier.issn1525-8610-
dc.identifier.urihttp://hdl.handle.net/10722/338302-
dc.description.abstract<h3>Objectives</h3><p>The aim of this study was to compare incidences of adverse events of special interest (AESI) and delirium in 3 cohorts: after COVID-19 vaccination, prepandemic, and SARS-CoV-2 polymerase chain reaction (PCR) test positive.</p><h3>Design</h3><p>This is a population-based cohort study using electronic medical records linked with vaccination records in Hong Kong.</p><h3>Setting and Participants</h3><p>A total of 17,449 older people with dementia received at least 1 dose of CoronaVac (n = 14,719) or BNT162b2 (n = 2730) between February 23, 2021, and March 31, 2022. Moreover, 43,396 prepandemic and 3592 SARS-CoV-2 test positive patients were also included in this study.</p><h3>Methods</h3><p>The incidences of AESI and delirium up to 28 days after vaccination in the vaccinated dementia cohort were compared with the prepandemic and SARS-CoV-2 test positive dementia cohorts by calculating incidence rate ratios (IRRs). Patients who received multiple doses were followed up separately for each dose, up to the third dose.</p><h3>Results</h3><p>We did not detect an increased risk of delirium and most AESI following vaccination compared to the prepandemic period and those tested positive for SARS-CoV-2. No AESI group nor delirium incidence exceeded 10 per 1000 person-days in vaccinated individuals.</p><h3>Conclusions and Implications</h3><p>The findings provide evidence for the safe use of COVID-19 vaccines in older patients with dementia. In the short run, benefit appears to outweigh the harm due to vaccine; however, longer follow-up should be continued to identify remote adverse events.</p>-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofJournal of the American Medical Directors Association-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectadverse events-
dc.subjectCOVID-19 vaccine-
dc.subjectdelirium-
dc.subjectdementia-
dc.subjectvaccine safety-
dc.titleRisk of Adverse Events and Delirium after COVID-19 Vaccination in Patients Living with Dementia-
dc.typeArticle-
dc.identifier.doi10.1016/j.jamda.2023.04.003-
dc.identifier.scopuseid_2-s2.0-85159231252-
dc.identifier.volume24-
dc.identifier.issue6-
dc.identifier.spage892-
dc.identifier.epage900-
dc.identifier.isiWOS:001046626600001-
dc.identifier.issnl1525-8610-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats